吉西他滨治疗复发、难治性非霍奇金淋巴瘤疗效的研究进展

摘要

我国淋巴瘤的主要分型为非霍奇金淋巴瘤（ non-Hodgkin′s lymphoma，NHL），其经典的化疗方案为CHOP方案，50%-60%的患者获得完全缓解，但其中一半病例出现复发或者发展为难治型病例。对于这部分患者目前迫切需要寻找一种高效、低毒的治疗方案。本文就几个主要包含吉西他滨的方案在中国人群中治疗复发、难治性非霍奇金淋巴瘤的疗效做一综述。%The main type of lymphoma in China is non-Hodgkin′s lymphoma( non-Hodgkin′s lymphoma,NHL). The classic chemotherapy scheme for the CHOP,50% -60% of the patients received complete remission,but half of cases will be recurrent or develop difficult cases. In this part of patients there is an urgent need to find a high efficient and low toxicity treatment. In this paper,several main contain gemcitabine scheme in the Chinese population with of recurrent and refractory non-hodgkin′s lymphoma were reviewed.